$5.14 Bn Castration-sensitive Prostate Cancer Market Insights, Epidemiology, and Forecasts, 2022-2026 & 2026-2036

Dublin, April 13, 2026 (GLOBE NEWSWIRE) -- The "Castration-sensitive Prostate Cancer - Market Insights, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering.

The treatment landscape for metastatic CSPC has evolved, with ADT being complemented by more intensive approaches. Recent advancements include the approval of XTANDI for non-metastatic CSPC in the US, opening new treatment opportunities. The total market size of CSPC in the US was approximately USD 2.58 billion in 2024, and significant growth is expected within the forecast period.

Castration Sensitive Prostate Cancer Drugs Uptake

NUBEQA exhibits strong global uptake, with ERLEADA demonstrating superior real-world survival and PSA response advantages. Novel therapies in pivotal trials must choose appropriate comparators for favorable regulatory outcomes and market acceptance.

Market Access and Reimbursement

Reimbursement is crucial for market access, impacting therapeutic availability. For instance, ORGOVYX's recommendation by NICE highlights evolving access for new therapies. XTANDI, paired with ADT, secures strong positioning in first-line mHSPC treatment.

Key Conference Highlights

Reasons to Buy the Castration Sensitive Prostate Cancer Market Report

Key Highlights

Castration Sensitive Prostate Cancer Market and Epidemiology Analysis

Castration Sensitive Prostate Cancer Market Size and Forecast

Key Factors Driving Growth

Companies Featured

For more information about this report visit https://www.researchandmarkets.com/r/4z75ig

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.